Principal Financial Group Inc. trimmed its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 1.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 228,759 shares of the company’s stock after selling 3,981 shares during the quarter. Principal Financial Group Inc. owned approximately 0.47% of Amphastar Pharmaceuticals worth $13,147,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its position in shares of Amphastar Pharmaceuticals by 396.7% during the third quarter. Price T Rowe Associates Inc. MD now owns 808,731 shares of the company’s stock worth $22,727,000 after acquiring an additional 645,917 shares during the last quarter. Granite Investment Partners LLC bought a new position in shares of Amphastar Pharmaceuticals during the first quarter worth about $20,131,000. Bank of America Corp DE raised its position in shares of Amphastar Pharmaceuticals by 347.2% during the first quarter. Bank of America Corp DE now owns 290,737 shares of the company’s stock worth $10,903,000 after acquiring an additional 225,728 shares during the last quarter. State Street Corp raised its position in shares of Amphastar Pharmaceuticals by 16.6% during the second quarter. State Street Corp now owns 1,540,846 shares of the company’s stock worth $53,606,000 after acquiring an additional 218,895 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Amphastar Pharmaceuticals by 183.2% during the second quarter. Goldman Sachs Group Inc. now owns 329,843 shares of the company’s stock worth $11,475,000 after acquiring an additional 213,355 shares during the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on AMPH shares. Bank of America started coverage on Amphastar Pharmaceuticals in a report on Friday. They issued a “neutral” rating and a $63.00 target price for the company. Piper Sandler lifted their target price on Amphastar Pharmaceuticals from $66.00 to $71.00 in a report on Wednesday, August 9th. Jefferies Financial Group started coverage on Amphastar Pharmaceuticals in a report on Tuesday, July 25th. They issued a “buy” rating and a $70.00 target price for the company. Finally, StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, November 13th.
Amphastar Pharmaceuticals Trading Down 0.6 %
NASDAQ AMPH opened at $55.85 on Friday. The company has a market cap of $2.73 billion, a price-to-earnings ratio of 21.82 and a beta of 0.87. Amphastar Pharmaceuticals, Inc. has a 52 week low of $27.58 and a 52 week high of $67.66. The business has a 50 day moving average price of $47.41 and a 200-day moving average price of $50.47. The company has a quick ratio of 1.68, a current ratio of 2.11 and a debt-to-equity ratio of 1.07.
In other news, CFO William J. Peters sold 60,743 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $51.75, for a total transaction of $3,143,450.25. Following the completion of the sale, the chief financial officer now owns 101,360 shares in the company, valued at $5,245,380. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Yakob Liawatidewi sold 28,816 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $53.13, for a total transaction of $1,530,994.08. Following the transaction, the executive vice president now owns 69,669 shares of the company’s stock, valued at $3,701,513.97. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO William J. Peters sold 60,743 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $51.75, for a total value of $3,143,450.25. Following the transaction, the chief financial officer now directly owns 101,360 shares in the company, valued at approximately $5,245,380. The disclosure for this sale can be found here. Insiders sold a total of 95,559 shares of company stock worth $4,982,484 over the last quarter. 28.40% of the stock is currently owned by corporate insiders.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).
- Five stocks we like better than Amphastar Pharmaceuticals
- How to Invest in Energy
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to Start Investing in Real Estate
- MarketBeat Week in Review – 11/13 – 11/17
- What is the S&P/TSX Index?
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.